Location History:
- Iwakuni, JA (1976 - 1978)
- Fuchu, JA (1978)
- Iwakuni, JP (1978 - 1980)
- Fuchu, JP (1979 - 1981)
- Tokorozawa, JP (1987 - 1996)
Company Filing History:
Years Active: 1976-1996
Areas of Expertise:
Title: Yataro Ichikawa: Innovator in Human Plasmin Inhibition
Introduction:
Yataro Ichikawa, based in Tokorozawa, Japan, stands out as an accomplished inventor with a remarkable portfolio comprising 46 patents. He has made significant contributions to the field of biomedical innovation, particularly in developing proteins and antibodies that target human plasmin inhibitors.
Latest Patents:
Ichikawa’s latest patents include groundbreaking inventions that focus on human plasmin inhibition. One of his prominent patents describes a protein exhibiting human plasmin inhibiting activity, with a molecular weight ranging from approximately 50,000 to 77,000. This protein shows substantial reactivity with human plasmin, akin to the human α2-plasmin inhibitor derived from plasma.
Another notable patent involves a monoclonal antibody specifically designed to target the human α2-plasmin inhibitor. This antibody has the unique ability to specifically block the site responsible for inhibiting the fibrinolytic activity of plasmin, thereby aiding in the treatment of thrombotic diseases. Furthermore, this invention includes a hybridoma that produces this monoclonal antibody, enhancing its utility in both immunological determinations and recovery of the human α2-plasmin inhibitor from various liquids.
Career Highlights:
Yataro Ichikawa's career is marked by his dedication to research and development at Teijin Limited. His work has not only advanced scientific understanding but has also paved the way for innovative therapeutic approaches. Through his inventions, Ichikawa has contributed significantly to the fields of hematology and cardiovascular health.
Collaborations:
Collaborating closely with esteemed colleagues such as Koji Nakagawa and Teizo Yamaji, Ichikawa has fostered a productive research environment. These partnerships have been instrumental in driving innovation and expanding the scope of research in human plasmin inhibition and related therapies.
Conclusion:
Yataro Ichikawa’s contributions to the field of biomedical innovation are noteworthy, with 46 patents reflecting his commitment to advancing healthcare solutions. His pioneering work on human plasmin inhibitors through proteins and monoclonal antibodies signifies a significant leap in therapeutic potential, showcasing his role as a key player in modern biomedical research.